Sana’s cell therapy may be ‘transformative cure’ for type 1 diabetes: analysts
Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes, sending the company’s share price up by about 200%. | Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with type 1 diabetes,
Sana Biotechnology’s Hypoimmune Platform: A Transformative Breakthrough in Type 1 Diabetes Treatment and Beyond
Samantha Semenkow, an analyst from Citi, maintained the Buy rating on Sana Biotechnology (SANA – Research Report). The associated price target
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable [clinical] result” cheered Wall Street, which led shares of the Seattle-based firm (NASDAQ:SANA) to close Jan.
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection,
Sana Biotechnology up 285% afterhours following type 1 diabetes study data
EST Sana Biotechnology (SANA) up 285% afterhours following type 1 diabetes study dataStay Ahead of the Market:Discover outperforming
Hosted on MSN1d
Sana Biotech Stock Triples After Type 1 Diabetes Trial Wows Analysts: Retail Erupts In Excitement
Sana Biotechnology Inc.'s stock soared over 200% on Wednesday, on track to mark its best day on record, amid trading volumes ...
Sana Biotech extends rally as Morgan Stanley cites platform's potential
Sana Biotechnology (SANA) stock soared after Phase 1 data for its cell therapy which, according to Morgan Stanley, has ...
Sana Biotechnology’s Promising UP421 Results and Potential Upside: A Buy Rating Affirmed
Analyst Vikram Purohit from Morgan Stanley maintained a Buy rating on Sana Biotechnology (SANA – Research Report) and keeping the price target ...
Hosted on MSN1d
TD Cowen Upgrades Sana Biotechnology (SANA)
Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Sana Biotechnology (NasdaqGS:SANA) from Hold to ...
Sana Biotechnology: Stock Price Rise Deserved Post Diabetes Cell Therapy Success
Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...
BioPharma Dive1d
Tenvie raises $200M for brain drug R&D; Sana spikes on single patient’s results
The Arch-backed startup begins life with several assets acquired from Denali Therapeutics. Elsewhere, Jasper got a negative ...
bovnews1d
Sana Biotechnology’s (SANA) Revolutionary Breakthrough Sends Stock Soaring
Sana Biotechnology’s innovative approach to treating type 1 diabetes centers around its HIP-modified pancreatic islet cell transplant. In the context of type 1 diabetes, the body’s immune system ...
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why
Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the 43 rd Annual J.P ...